The email below is in response to a factually inaccurate Military Times article that stated the Congressionally Directed Medical Research Programs (CDMRP) were being funded through raised TRICARE rates.
The U.S. House Appropriations Committee clarified that assertion is false.
The email is from Mark Vieth, who represents two rare disease organizations and has taken a leading role in lashing together a broad coalition of CDMRP support groups.
--Anthony Hardie, Madison, Wis.
Many of you may have seen an article published in Army Times or Navy Times that suggested that the CDMRPs are funded through reductions in the TRICARE budget.
I asked Brooke Boyer on the House Appropriations Committee if there was any validity to this, and I wanted to share her response below:
“This article is not factually correct.
"Every mark in our bill is done on an individual basis; one mark that decreases funds does not have anything to do with a mark that increases funds elsewhere. Furthermore, the $330 million that was reduced is FY12 money in the budget request, not FY11 money.
"TRICARE funding is operation and maintenance funding, which is only available for one year. The Committee believes that the budget request overestimates the amount of TRICARE funding necessary in FY12, hence the reduction.”
Mark D. Vieth, Senior Vice PresidentCavarocchi Ruscio Dennis AssociatesWashington, DC
The flawed information in the Military Times article appears to have been based on the following